文献速递淋巴瘤

基线18FDG-PET/CT扫描的代谢异质性是原发纵隔B细胞淋巴瘤结局的预测因素

Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma.
PubMed 文献 · Blood · 2018-05-02

在IELSG 26研究前瞻性入组的103例原发纵隔B细胞淋巴瘤患者中,用AUC-CSH法评估基线18FDG-PET/CT的代谢异质性,低代谢异质性与高代谢异质性组5年无进展生存率分别为94%与73%(P=.0001),多因素分析中仅总病灶糖酵解与代谢异质性保持独立预后意义。

要点

  • 低代谢异质性组5年无进展生存率94%,高代谢异质性组73%(P=.0001)。
  • 多因素Cox模型中仅总病灶糖酵解(P<.001)与代谢异质性(P<.001)保持统计学显著性。
  • 两特征构建的简易预后模型可早期准确识别高危进展患者(阳性预测值89%,阴性预测值≥90%)。

核心结论

  • 基线代谢异质性是原发纵隔B细胞淋巴瘤的预后预测因素,与总病灶糖酵解联合可早期识别高危进展患者。
  • 该结果可能为针对化疗耐药患者的未来试验设计提供机会。

研究设计与样本

  • 前瞻性入组国际结外淋巴瘤研究组(IELSG)26研究的103例原发纵隔B细胞淋巴瘤患者。
  • 采用累积标准化摄取值-体积直方图曲线下面积(AUC-CSH)法评估代谢异质性。
  • 研究注册于ClinicalTrials.gov,注册号NCT00944567。

主要发现

  • 低代谢异质性组5年无进展生存率为94%,高代谢异质性组为73%(P=.0001)。
  • 包含二分类代谢异质性、代谢肿瘤体积、总病灶糖酵解、国际预后指数、肿瘤负荷(纵隔肿块>10 cm)及年龄(连续变量)的Cox模型中,仅总病灶糖酵解(P<.001)与代谢异质性(P<.001)保持统计学显著性。
  • 用代谢异质性与总病灶糖酵解构建的简易预后模型识别进展高危患者的阳性预测值为89%,阴性预测值≥90%。

关键数值与推荐

  • 代谢异质性采用AUC-CSH法评估。
  • 肿瘤负荷定义为纵隔肿块>10 cm。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

An important unmet need in the management of primary mediastinal B-cell lymphoma (PMBCL) is to identify the patients for whom first-line therapy will fail to intervene before the lymphoma becomes refractory. High heterogeneity of intratumoral 18F-fluorodeoxyglucose (18FDG) uptake distribution on positron emission tomography/computed tomography (PET/CT) scans has been suggested as a possible marker of chemoresistance in solid tumors. In the present study, we investigated the prognostic value of metabolic heterogeneity (MH) in 103 patients with PMBCL prospectively enrolled in the International Extranodal Lymphoma Study Group (IELSG) 26 study, aimed at clarifying the role of PET in this lymphoma subtype. MH was estimated using the area under curve of cumulative standardized uptake value-volume histogram (AUC-CSH) method. Progression-free survival at 5 years was 94% vs 73% in low- and high-MH groups, respectively (P = .0001). In a Cox model of progression-free survival including dichotomized MH, metabolic tumor volume, total lesion glycolysis (TLG), international prognostic index, and tumor bulk (mediastinal mass > 10 cm), as well as age as a continuous variable, only TLG (P < .001) and MH (P < .001) retained statistical significance. Using these 2 features to construct a simple prognostic model resulted in early and accurate (positive predictive value, 89%; negative predictive value, ≥90%) identification of patients at high risk for progression at a point that would allow the use of risk-adapted treatments. This may provide an important opportunity for the design of future trials aimed at helping the minority of patients who harbor chemorefractory PMBCL. The study is registered at ClinicalTrials.gov as NCT00944567.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Ceriani L, Milan L, Martelli M, et al. Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. Blood. 2018. PMID: 29720487. doi:10.1182/blood-2018-01-826958

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。